Open Journal Systems

Therapeutic Targets and Predictive Markers of Treatment Efficacy of Bladder Cancer

VIEWS - 56 (Abstract) 33 (PDF)
Mengran Shi, Luyao Wang, Zhao Yang, Chong Li


Bladder cancer (BC) is one of the most common types of cancers in the world. Despite various treatments are currently in place, the prognosis of BC does not seem to improve. Therefore, this prompts us to search for alternative treatments. The understanding of the molecular changes in cancer offers the prospect of targeting the key elements responsible for cancer development and progression, and thus, helps to develop a more effective and robust targeted therapy that does not endanger normal cells. At present, protein-based therapeutic targets such as programmed death ligand 1, epidermal growth factor receptor and aberrantly glycosylated integrin-α3β1, and genetic targets such as p53, human EGF receptor-2, and miR-23b are promising targets for BC treatment. In addition, predictive markers of treatment efficacy for BC, such as meiotic recombination 11, excision repair cross-complementing group 1, and multidrug resistance 1 gene are essential in facilitating clinicians to design and implement suitable and effective therapies for BC patients. This review discusses the pivotal role of these markers in the development of targeted therapy and the estimation of the clinical outcome of BC.


Bladder cancer, Therapeutic targets, Therapeutic efficacy, Programmed death-ligand 1, Excisio repair cross-complementing group 1

Full Text:



Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 68:394–424. DOI: 10.3322/ caac.21492.

Hindy JR, Souaid T, Kourie HR, et al., 2019, Targeted Therapies in Urothelial Bladder Cancer: A Disappointing Past Preceding a Bright Future? Future Oncol, 15:1505-24. DOI: 10.2217/fon-2018-0459.

Czerniak B, Dinney C, McConkey D, 2016, Origins of Bladder Cancer. Annu Rev Pathol, 11:149–74. DOI: 10.1146/annurev-pathol-012513-104703.

Anastasiadis A, de Reijke TM, 2012, Best Practice in the Treatment of Nonmuscle Invasive Bladder Cancer. Ther Adv Urol, 4:13–32. DOI: 10.1177/1756287211431976.

Sawyers C, 2004, Targeted Cancer Therapy. Nature, 432:294–7.

Zhang Q, Wang Z, Guo J, et al., 2015, Comparison of Single-agent Chemotherapy and Targeted Therapy to First-line Treatment in Patients Aged 80 Years and Older with Advanced Non-small-cell Lung Cancer. Onco Targets Ther, 8:893–8. DOI: 10.2147/ott.s81837.

Montazeri K, Bellmunt J, 2020, Erdafitinib for the Treatment of Metastatic Bladder Cancer. Expert Rev Clin Pharmacol, 13:1–6.

Inman BA, Longo TA, Ramalingam S, et al., 2017, Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res, 23:1886–90. DOI: 10.1158/1078- 0432.ccr-16-1417.

Freeman, G.J, Long AJ, Iwai Y, et al., 2000, Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med, 192:1027–34. DOI: 10.1084/ jem.192.7.1027.

Wakabayashi G, Lee YC, Luh F, et al., 2019, Development and Clinical Applications of Cancer Immunotherapy against PD-1 Signaling Pathway. J Biomed Sci, 26:96. DOI: 10.1186/s12929-019-0588-8.

Chen DS., Irving BA, Hodi FS, 2012, Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clin Cancer Res, 18:6580–7. DOI: 10.1158/1078-0432.ccr-12-1362.

Elfving H, Mattsson JS, Lindskog C, et al., 2019, Programmed Cell Death Ligand 1 Immunohistochemistry: A Concordance Study Between Surgical Specimen, Biopsy, and Tissue Microarray. Clin Lung Cancer, 20:258–62. DOI: 10.1016/j.cllc.2019.02.012.

Azuma T, Yao S, Zhu G, et al., 2008, B7-H1 is a Ubiquitous Antiapoptotic Receptor on Cancer Cells. Blood, 111:3635– 43. DOI: 10.1182/blood-2007-11-123141.

Sun C, Mezzadra R, Schumacher TN, 2018, Regulation and Function of the PD-L1 Checkpoint. Immunity, 48:434–52. DOI: 10.1016/j.immuni.2018.03.014.

van der Vlist M, Kuball J, Radstake TR, et al., 2016, Immune Checkpoints and Rheumatic Diseases: What Can Cancer Immunotherapy Teach Us? Nat Rev Rheumatol, 12:593–604. DOI: 10.1038/nrrheum.2016.131.

Gubin MM, Zhang X, Schuster H, et al., 2014, Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens. Nature, 515:577–81.

Smyth MJ, Teng MW, 2018, Nobel Prize in Physiology or Medicine. Clin Transl Immunol, 7:e1041. DOI: 10.1002/ cti2.1041.

Powles T, Eder JP, Fine GD, et al., 2014, MPDL3280A (anti-PD-L1) Treatment Leads to Clinical Activity in Metastatic Bladder Cancer. Nature, 515:558–62. DOI: 10.1038/nature13904.

Brower V, 2016, Anti-PD-L1 Inhibitor Durvalumab in Bladder Cancer. Lancet Oncol, 17:e275. DOI: 10.1016/ s1470-2045(16)30242-x.

Apolo AB, Infante JR, Balmanoukian A, et al., 2017, Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol, 35:2117–24. DOI: 10.1200/jco.2016.71.6795.

Cree IA, Booton R, Cane P, et al., 2016, PD-L1 Testing for Lung Cancer in the UK: Recognizing the Challenges for Implementation. Histopathology, 69:177–86. DOI: 10.1111/his.12996.

Gosney JR, Boothman AM, Ratcliffe M, et al., 2020, Cytology for PD-L1 Testing: A Systematic Review. Lung Cancer, 141:101–6. DOI: 10.1016/j.lungcan.2020.01.010.

Maute RL, Gordon SR, Mayer AT, et al., 2015, Engineering High-affinity PD-1 Variants for Optimized Immunotherapy and Immuno-PET Imaging. Proc Natl Acad Sci USA, 112:6506–14. DOI: 10.1073/pnas.1519623112.

Patel SJ, Sanjana NE, Kishton RJ, et al., 2017, Identification of Essential Genes for Cancer Immunotherapy. Nature, 548:537–42.

Liu H, Kuang X, Zhang Y, et al., 2020, ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3- PD-L1 Axis. Cancer Cell, 37:324–39. DOI: 10.1016/j. ccell.2020.02.006.

Rebouissou S, Bernard-Pierrot I, de Reyniès A, et al., 2014, EGFR as a Potential Therapeutic Target for a Subset of Muscle-Invasive Bladder Cancers Presenting a Basal-Like Phenotype. Sci Transl Med, 6:244ra291.

Appert-Collin A, Hubert P, Cremel G, et al., 2015, Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol, 6:283. DOI: 10.3389/fphar.2015.00283.

Pruthi RS, Nielsen M, Heathcote S, et al., 2010, A Phase II Trial of Neoadjuvant Erlotinib in Patients with Muscle- Invasive Bladder Cancer Undergoing Radical Cystectomy: Clinical and Pathological Results. BJU Int, 106:349–54. DOI: 10.1111/j.1464-410x.2009.09101.x.

Wong YN, Litwin S, Vaughn D, et al., 2012, Phase II Trial of Cetuximab with or Without Paclitaxel in Patients with Advanced Urothelial Tract Carcinoma. J Clin Oncol, 30:3545–51. DOI: 10.1200/jco.2012.41.9572.

Joly F, Houédé N, Noal S, et al., 2009, Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study. Clin Genitourin Cancer, 7:E28–33. DOI: 10.3816/cgc.2009.n.018.

Chang L, Shi R, Yang T, et al., 2013, Restoration of LRIG1 Suppresses Bladder Cancer Cell Growth by Directly Targeting EGFR Activity. J Exp Clin Cancer Res, 32:101. DOI: 10.1186/1756-9966-32-101.

Gur G, Rubin C, Katz M, et al., 2004, LRIG1 Restricts Growth Factor Signaling by Enhancing Receptor Ubiquitylation and Degradation. EMBO J, 23:3270–81. DOI: 10.1038/sj.emboj.7600342.

Yan Z, Jiang J, Li F, et al., 2015, Adenovirus-Mediated LRIG1 Expression Enhances the Chemosensitivity of Bladder Cancer Cells to Cisplatin. Oncol Rep, 33:1791–8. DOI: 10.3892/or.2015.3807.

Kreidberg JA, 2000, Functions of Alpha3beta1 Integrin. Curr Opin Cell Biol, 12:548–53.

Li C, Yang Z, Du Y, et al., 2014, BCMab1, a Monoclonal Antibody against Aberrantly Glycosylated Integrin Alpha3beta1, has Potent Antitumor Activity of Bladder Cancer In Vivo. Clin Cancer Res, 20:4001–13. DOI: 10.1158/1078-0432.ccr-13-3397.

Li C, Yan R, Yang Z, et al., 2017, BCMab1-Ra, a Novel Immunotoxin that BCMab1 Antibody Coupled to Ricin A Chain, Can Eliminate Bladder Tumor. Oncotarget, 8:46704–5. DOI: 10.18632/oncotarget.13504.

Li C, Du Y, Yang Z, et al., 2016, GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells. Cancer Res, 76:1273–83. DOI: 10.1158/0008-5472.can-15-2309.

Jia ZM, Ai X, Teng JF, et al., 2016, p21 and CK2 Interaction-Mediated HDAC2 Phosphorylation Modulates KLF4 Acetylation to Regulate Bladder Cancer Cell Proliferation. Tumour Biol, 37:8293–304. DOI: 10.1007/ s13277-015-4618-1.

Lae M, Couturier J, Oudard S, et al., 2010, Assessing HER2 Gene Amplification as a Potential Target for Therapy in Invasive Urothelial Bladder Cancer with a Standardized Methodology: Results in 1005 Patients. Ann Oncol, 21:815– 9. DOI: 10.1093/annonc/mdp488.

Wei L, Chintala S, Ciamporcero E, et al., 2016, Genomic Profiling is Predictive of Response to Cisplatin Treatment but not to PI3K Inhibition in Bladder Cancer Patient-derived Xenografts. Oncotarget, 7:76374–89. DOI: 10.18632/ oncotarget.13062.

Quan J, Pan X, Zhao L, et al., 2018, LncRNA as a Diagnostic and Prognostic Biomarker in Bladder Cancer: A Systematic Review and Meta-Analysis. Onco Targets Ther, 11:6415–24.

Goldhirsch A, Wood WC, Gelber RD, et al., 2007, Progress and Promise: Highlights of the International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007. Ann Oncol, 18:1133–44. DOI: 10.1093/annonc/ mdm271.

Jimenez RE, Hussain M, Bianco FJ Jr., et al., 2001, Her- 2/neu Overexpression in Muscle-Invasive Urothelial Carcinoma of the Bladder: Prognostic Significance and Comparative Analysis in Primary and Metastatic Tumors. Clin Cancer Res, 7:2440–7.

Matsubara H., Yamada Y, Naruse K, et al., 2008, Potential for HER-2/neu Molecular Targeted Therapy for Invasive Bladder Carcinoma: Comparative Study of Immunohistochemistry and Fluorescent In Situ Hybridization. Oncol Rep, 19:57–63. DOI: 10.3892/or.19.1.57.

Hansel DE, Swain E, Dreicer R, et al., 2008, HER2 Overexpression and Amplification in Urothelial Carcinoma of the Bladder is Associated with MYC Coamplification in a Subset of Cases. Am J Clin Pathol, 130:274–81. DOI: 10.1309/41vltfx3ypp1hf6f.

Uchida Y, Chiyomaru T, Enokida H, et al., 2013, MiR-133a Induces Apoptosis through Direct Regulation of GSTP1 in Bladder Cancer Cell Lines. Urol Oncol, 31:115–23. DOI: 10.1016/j.urolonc.2010.09.017.

Majid S, Dar AA, Saini S, et al., 2013, MicroRNA-23b Functions as a Tumor Suppressor by Regulating Zeb1 in Bladder Cancer. PLoS One, 8:e67686. DOI: 10.1371/ journal.pone.0067686.

Lavin MF, 2007, ATM and the Mre11 Complex Combine to Recognize and Signal DNA Double-strand Breaks. Oncogene, 26:7749–58. DOI: 10.1038/sj.onc.1210880.

Choudhury A, Nelson LD, Teo MT, et al., 2010, MRE11 Expression is Predictive of Cause-specific Survival Following Radical Radiotherapy for Muscle-invasive Bladder Cancer. Cancer Res, 70:7017–26. DOI: 10.1158/0008-5472.can-10-1202.

Laurberg JR, Brems-Eskildsen AS, Nordentoft I, et al., 2012, Expression of TIP60 (tat-Interactive Protein) and MRE11 (Meiotic Recombination 11 Homolog) Predict Treatment-Specific Outcome of Localised Invasive Bladder Cancer. BJU Int, 110:E1228–36. DOI: 10.1111/j.1464- 410x.2012.11564.x.

Teo MT, Dyrskjøt L, Nsengimana J, et al., 2014, Next- Generation Sequencing Identifies Germline MRE11A Variants as Markers of Radiotherapy Outcomes in Muscle-invasive Bladder Cancer. Ann Oncol, 25:877–83. DOI: 10.1093/annonc/mdu014.

Ahmad A, Robinson AR, Duensing A, et al., 2008, ERCC1-XPF Endonuclease Facilitates DNA Double-strand Break Repair. Mol Cell Biol, 28:5082–92. DOI: 10.1128/ mcb.00293-08.

Kawashima A, Nakayama M, Kakuta Y, et al., 2011, Excision Repair Cross-complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle- Invasive Bladder Cancer. Clin Cancer Res, 17:2561–9. DOI: 10.1158/1078-0432.ccr-10-1963.

Bellmunt J, Paz-Ares L, Cuello M, et al., 2007, Gene Expression of ERCC1 as a Novel Prognostic Marker in Advanced Bladder Cancer Patients Receiving Cisplatin- Based Chemotherapy. Ann Oncol, 18:522–8. DOI: 10.1093/ annonc/mdl435.

Sun JM, Sung JY, Park SH, et al., 2012, ERCC1 as a Biomarker for Bladder Cancer Patients Likely to Benefit from Adjuvant Chemotherapy. BMC Cancer, 12:187. DOI: 10.1186/1471-2407-12-187.

Clifford SC, Neal DE, Lunec J, 1996, High Level Expression of the Multidrug Resistance (MDR1) Gene in the Normal Bladder Urothelium: A Potential Involvement in Protection against Carcinogens? Carcinogenesis, 17:601–4. DOI: 10.1093/carcin/17.3.601.

Tada Y, Wada M, Kuroiwa K, et al., 2000, MDR1 Gene Overexpression and Altered Degree of Methylation at the Promoter Region in Bladder Cancer During Chemotherapeutic Treatment. Clin Cancer Res, 6:4618–27.

Cheng XZ, Zhou HL, Tang SX, et al., 2019, Intercellular Transfer of P-Glycoprotein Mediates the Formation of Stable Multi-Drug Resistance in Human Bladder Cancer BIU-87 Cells. Biol Open, 8:bio041889. DOI: 10.1242/ bio.041889.

Tada Y, Wada M, Migita T, et al., 2002, Increased Expression of Multidrug Resistance-Associated Proteins in Bladder Cancer during Clinical Course and Drug Resistance to Doxorubicin. Int J Cancer, 98:630–35. DOI: 10.1002/ijc.10246.

Hoffmann AC, Wild P, Leicht C, et al., 2010, MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy. Neoplasia, 12:628–36. DOI: 10.1593/neo.10402.

Ciccia A, Elledge SJ, 2010, The DNA Damage Response: Making it Safe to Play with Knives. Mol Cell, 40:179–204. DOI: 10.1016/j.molcel.2010.09.019.

Dick FA, Goodrich DW, Sage J, et al., 2018, Non-Canonical Functions of the RB Protein in Cancer. Nat Rev Cancer, 18:442–51. DOI: 10.1038/s41568-018-0008-5.

Yin M, Grivas P, Emamekhoo H, et al., 2018, ATM/ RB1 Mutations Predict Shorter Overall Survival in Urothelial Cancer. Oncotarget, 9:16891–8. DOI: 10.18632/ oncotarget.24738.

He H, Chang R, Zhang T, et al., 2017, ATM Mediates DAB2IP-Deficient Bladder Cancer Cell Resistance to Ionizing Radiation through the p38MAPK and NF-kappaB Signaling Pathway. Mol Med Rep, 16:1216–22. DOI: 10.3892/mmr.2017.6689.

Neveling K, Kalb R, Florl AR, et al., 2007, Disruption of the FA/BRCA Pathway in Bladder Cancer. Cytogenet Genome Res, 118:166–76. DOI: 10.1159/000108297.

Plimack ER, Dunbrack RL, Brennan TA, et al., 2015, Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur Urol, 68:959–67. DOI: 10.3410/f.725696741.793526237.

Miron B, Hoffman-Censits JH, Anari F, et al., 2020, Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol Oncol, 10:S2588. DOI: 10.1016/j.euo.2020.02.003.



  • There are currently no refbacks.

Copyright (c) 2020 Shi, et al.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recent Articles | About Journal | For Author | Fees | About Whioce

Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.